MianserinCAS# 24219-97-4 |
2D Structure
- Bavisant dihydrochloride hydrate
Catalog No.:BCC1404
CAS No.:1103522-80-0
- Lidocaine
Catalog No.:BCC1084
CAS No.:137-58-6
- Loratadine
Catalog No.:BCC1262
CAS No.:79794-75-5
- Bavisant
Catalog No.:BCC1402
CAS No.:929622-08-2
- Bavisant dihydrochloride
Catalog No.:BCC1403
CAS No.:929622-09-3
Quality Control & MSDS
3D structure
Package In Stock
Number of papers citing our products
Cas No. | 24219-97-4 | SDF | Download SDF |
PubChem ID | 4184 | Appearance | Powder |
Formula | C18H20N2 | M.Wt | 264.36 |
Type of Compound | N/A | Storage | Desiccate at -20°C |
Solubility | Soluble in DMSO | ||
SMILES | CN1CCN2C(C1)C3=CC=CC=C3CC4=CC=CC=C42 | ||
Standard InChIKey | UEQUQVLFIPOEMF-UHFFFAOYSA-N | ||
Standard InChI | InChI=1S/C18H20N2/c1-19-10-11-20-17-9-5-3-7-15(17)12-14-6-2-4-8-16(14)18(20)13-19/h2-9,18H,10-13H2,1H3 | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Mianserin Dilution Calculator
Mianserin Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 3.7827 mL | 18.9136 mL | 37.8272 mL | 75.6544 mL | 94.568 mL |
5 mM | 0.7565 mL | 3.7827 mL | 7.5654 mL | 15.1309 mL | 18.9136 mL |
10 mM | 0.3783 mL | 1.8914 mL | 3.7827 mL | 7.5654 mL | 9.4568 mL |
50 mM | 0.0757 mL | 0.3783 mL | 0.7565 mL | 1.5131 mL | 1.8914 mL |
100 mM | 0.0378 mL | 0.1891 mL | 0.3783 mL | 0.7565 mL | 0.9457 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
Mianserin is a H1 receptor inverse agonist and is a psychoactive agent of the tetracyclic antidepressant.
- Tabimorelin hemifumarate
Catalog No.:BCC5897
CAS No.:242143-80-2
- Farrerol
Catalog No.:BCN2481
CAS No.:24211-30-1
- 3,3',4,4'-Benzophenone tetracarboxylic dianhydride
Catalog No.:BCC8593
CAS No.:2421-28-5
- Bis(4-hydroxy-3-methylphenyl) sulfide
Catalog No.:BCC8885
CAS No.:24197-34-0
- Epiyangambin
Catalog No.:BCN7029
CAS No.:24192-64-1
- Boc-Glu-OH
Catalog No.:BCC3386
CAS No.:2419-94-5
- H-Glu(OtBu)-OH
Catalog No.:BCC2933
CAS No.:2419-56-9
- H-Lys(Boc)-OH
Catalog No.:BCC2982
CAS No.:2418-95-3
- Zoniporide dihydrochloride
Catalog No.:BCC7461
CAS No.:241799-10-0
- Kobusone
Catalog No.:BCN5096
CAS No.:24173-71-5
- Epitulipinolide
Catalog No.:BCN5095
CAS No.:24164-13-4
- Trametenolic acid
Catalog No.:BCN3330
CAS No.:24160-36-9
- 3-Methyl-9H-carbazol-2-ol
Catalog No.:BCN4666
CAS No.:24224-30-4
- Thalictrimine
Catalog No.:BCN5097
CAS No.:24240-04-8
- Solifenacin succinate
Catalog No.:BCC4580
CAS No.:242478-38-2
- 2,5-Bis(4-aminophenyl)-1,3,4-oxadiazole
Catalog No.:BCC8501
CAS No.:2425-95-8
- H-Phe(4-Br)-OH
Catalog No.:BCC3157
CAS No.:24250-84-8
- H-Phe(4-I)-OH
Catalog No.:BCC3259
CAS No.:24250-85-9
- 7-Methoxy-8-Hydroxy-4-Phenylcoumarin
Catalog No.:BCC8292
CAS No.:24258-36-4
- Shikokianin
Catalog No.:BCN3278
CAS No.:24267-69-4
- Furanodienone
Catalog No.:BCN3010
CAS No.:24268-41-5
- Cannabidivarin
Catalog No.:BCN7536
CAS No.:24274-48-4
- Acetylcephalotaxine
Catalog No.:BCN5098
CAS No.:24274-60-0
- Sodium ferulic
Catalog No.:BCN8542
CAS No.:24276-84-4
The pharmacokinetics of mianserin suppositories for rectal administration in dogs and healthy volunteers: a pilot study.[Pubmed:27190632]
J Pharm Health Care Sci. 2016 May 17;2:12.
BACKGROUND: We formulated Mianserin suppositories for the treatment of delirium and evaluated their pharmacokinetics by measuring plasma drug concentrations in dogs and healthy human volunteers. METHODS: Mianserin suppositories were prepared by a melting technique using Tetramide(R) tablets and Witepsol H-15 as the suppository base. Pharmacokinetics of this 30-mg Mianserin preparation were evaluated in three beagle dogs and three healthy adult males, in line with ethics committee approval. Plasma Mianserin levels were determined using gas chromatography-mass spectrometry. RESULTS: In dogs, the maximum plasma Mianserin concentration (Cmax) was 1.3 +/- 0.4 ng/mL, the time to Cmax (tmax) was 5.5 +/- 4.3 h, and the area under the plasma concentration-time curve from 0 to 24 h (AUC0-24) was 18.9 +/- 1.9 hng/mL. In humans, the Cmax was 14.6 +/- 6.3 ng/mL, the tmax was 8 h, and the AUC0-24 was 266 +/- 103 hng/mL. CONCLUSIONS: The current study characterized the pharmacokinetics of Mianserin suppositories in dogs and humans. As compared to oral administration, the suppositories produced a lower Cmax and a delayed tmax, although AUC0-24 values were comparable. It will be necessary to identify an appropriate dose that produces an adequate plasma Mianserin concentration for effective and safe clinical use. TRIAL REGISTRATION: UMIN000013853.
Quantum chemical study and isothermal titration calorimetry of beta-cyclodextrin complexes with mianserin in aqueous solution.[Pubmed:28090612]
Org Biomol Chem. 2017 Feb 1;15(5):1209-1216.
beta-Cyclodextrin (beta-CD) is studied as a carrier of the drug Mianserin (MIA). beta-CD with MIA adducts with 1 : 1 and 2 : 1 stoichiometry are investigated in vacuo and in water using quantum chemical methods: PM6 and B3LYP/6-31G(d,p). An effect of the dispersion correction GD2 and the basis set superposition error on the complexation energies is also evaluated. Additionally, the interaction between MIA hydrochloride and beta-CD in aqueous solution at 298.15 K is examined experimentally by isothermal titration calorimetry. Interaction parameters, such as the binding constant, enthalpy, entropy and Gibbs free energy, are presented. Analysis of the obtained data led to the following conclusions: the interaction of MIA with beta-CD is rather strong; there is no significant energetic difference between the 1 : 1 complexes of beta-CD with S-MIA and R-MIA enantiomers; the 2 : 1 (beta-CD : MIA) adduct is energetically more favorable than 1 : 1; the complex formation of MIA + beta-CD is enthalpy and entropy driven.
Traxoprodil augments the antidepressant-like activity of agomelatine but not of mianserin or tianeptine in the forced swim test in mice.[Pubmed:27371898]
Pharmacol Rep. 2016 Oct;68(5):960-3.
BACKGROUND: The main objective of our study was to evaluate the influence of traxoprodil on the activity of the atypical antidepressant drugs (agomelatine, Mianserin, tianeptine). METHODS: The forced swim test (FST) in mice was used to determine the antidepressant-like activity of the tested agents. Drugs levels in brain tissue were assessed by a high performance liquid chromatography method. RESULTS: Concurrent intraperitoneal administration of per se ineffective doses of traxoprodil (10mg/kg) and agomelatine (20mg/kg) shortened the immobility time of animals in the FST. The observed effect was associated with elevated brain levels of traxoprodil. Similar interaction was not detected for traxoprodil and Mianserin (10mg/kg) or tianeptine (15mg/kg). CONCLUSION: Traxoprodil-agomelatine interaction is pharmacokinetic in nature. A combination of these agents has a potential to become an interesting strategy in the treatment of depression.
Mianserin affects alarm reaction to conspecific chemical alarm cues in Nile tilapia.[Pubmed:27554252]
Fish Physiol Biochem. 2017 Feb;43(1):193-201.
In this study, I show that Mianserin, a chemical with serotonin and adrenoceptor antagonist activities, increases fish vulnerability to a potential predator threat, when prey fish must deal with this threat based on conspecific chemical alarm cues. For that, I evaluated whether Mianserin, diluted in the water, influences the behavioral responses of Nile tilapia (Oreochromis niloticus) to conspecific skin extract (chemical alarm cues). I found that, while Mianserin did not abolished antipredator responses, this drug mitigates some components of this defensive reaction. Thus, a potential decrease in serotonin and adrenergic activities reduces the ability of dealing with predators when perceiving conspecific chemical alarm cues.